Canakinumab fails to improve survival odds without ventilation in severe COVID-19

canakinumab fails to improve survival odds without ventilation in severe covid 19

Sumary of Canakinumab fails to improve survival odds without ventilation in severe COVID-19:

  • July 20, 2021 2 min read Source/Disclosures Published by: Disclosures: The researchers report funding Novartis.
  • Caricchio additionally reports grants from Janssen and personal fees from Janssen, GlaxoSmithKline, Bristol Myers Squibb, Eli Lilly &
  • Please see the study for all other authors’ relevant financial disclosures.
  • Back to Healio Canakinumab fails to significantly increase the likelihood of survival without accompanying invasive mechanical ventilation, compared with placebo, in patients with severe COVID-19, according to data published in JAMA.
  • “IL-1 is an upstream proinflammatory cytokine that is involved in the pathogenesis of a variety of autoinflammatory conditions and induces the production of secondary inflammatory mediators, including IL-6,” Roberto Caricchio, MD, of the Lewis Katz School of Medicine at Temple University, in Philadelphia, and colleagues wrote.
  • 2021.9508. “Postmortem examination of lungs of patients who died of COVID-19 pneumonia have revealed intense inflammasome formation,” they added.
  • ” To examine the efficacy of the IL-1 inhibitor canakinumab (Ilaris, Novartis), in patients who are hospitalized with severe COVID-19, Caricchio and colleagues conducted the CAN-COVID trial.
  • According to the researchers, this randomized, double-blind, placebo-controlled phase 3 study included 454 participants with COVID-19 pneumonia from 39 hospitals in Europe and the United States.

Want to know more click here go to source.

From -

Close
Generic selectors
Exact matches only
Search in title
Search in content

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close